A thousand dollars split across Realty Income, AbbVie, and Coca-Cola today would start pumping out $46 in cash every year—then keep growing as each management team raises the payout faster than inflation.
Why dividends still matter in a 5 % world
With one-month T-bills hovering near 4.5 %, investors can finally get paid to wait. Yet the best dividend stocks offer something bonds can’t: a built-in raise every year. The three names below combine above-market yields today with payout growth that historically crushes CPI.
Realty Income: the monthly “paycheck” REIT
Realty Income (NYSE: O) mails a check every 30 days, has done so for 667 consecutive months, and still yields 5.5 %—triple the S&P 500. Triple-net leases push taxes, insurance, and upkeep onto 1,600+ tenants including Lowe’s, Dollar General, and Wynn Resorts, letting the REIT pocket predictable rent bumps averaging 1 % a year. Occupancy held at 98.7 % across 15,500 properties in November 2025, a level most mall landlords can only dream of.
At 14-times 2026 estimated AFFO, the stock trades two turns below its ten-year median, giving new money a rare entry window while long rates stabilize.
AbbVie: 50+ years of raises hidden inside Big Pharma
AbbVie (NYSE: ABBV) has lifted its dividend at a 7 % annual clip since 2019, yet the payout ratio sits under 50 % of free cash flow—plenty of cushion for the next hike. The Humira cliff is old news: immunology and neuroscience sales rose 12 % and 20 % respectively in Q3 2026, while the late-stage pipeline now counts 90 programs. A 3.1 % starter yield looks modest next to Realty Income, but the growth kicker is why total-return investors keep coming back.
Shares change hands at 15.7-times forward earnings, a slight premium to the five-year average but still below Merck and Lilly—reasonable for a company on pace to clear $26 B in operating cash this year (AbbVie investor relations).
Coca-Cola: the 64-year dividend aristocrat trading at a discount
Coca-Cola (NYSE: KO) has increased its payout every year since 1962. Global case volume crept up only 1 % last quarter, yet pricing power pushed net revenue 5 % higher and expanded operating margin 180 bps—textbook evidence of a wide economic moat. A 22-times forward P/E sits just below the five-year average of 23, rare for a consumer staple that usually sports a scarcity premium.
The 2.9 % yield won’t knock your socks off, but the board’s historical 5 % annual raise plus relentless buybacks have translated into 11 % total shareholder return per year over the past three decades (Q3 2025 earnings release).
How to deploy your $1,000 right now
- $400 → Realty Income at $58 = 6.9 shares, $24.20 annual income
- $350 → AbbVie at $175 = 2.0 shares, $10.80 annual income
- $250 → Coca-Cola at $58 = 4.3 shares, $7.00 annual income
Total first-year cash: roughly $42—and every one of those dollars is scheduled to arrive again next year, only larger.
Risk check: what could go wrong
Rising real-estate cap rates would pressure Realty Income’s NAV premium. AbbVie still relies on blockbuster drugs; patent litigation or a trial failure could dent cash flow. Coke’s sugary drinks face regulatory headwinds in Europe and parts of Latin America. Offsetting these negatives: diversified tenant bases, deep pipelines, and unmatched distribution scale.
Bottom line: locking in these three names today gives you an instant 4.2 % blended yield with a built-in cost-of-living adjustment. Reinvest the cash, add on dips, and let the calendar—not CNBC—do the compounding. For more fastest-in-class income ideas, keep reading onlytrustedinfo.com.
